RxDoctor Payments Data

Rachel Sedgewick, PA

Family Medicine · Holt, MINPI 1396352894

Payments from drug & device makers

$3,045in general payments, 2019–2025

Across 121 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$814
  • Novo Nordisk$401
  • AstraZeneca$282
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$263
  • Lilly USA, LLC$203
  • Nestle Healthcare Nutrition Inc.$150
  • plus $932 from 19 others

What the payments were for

  • Food & beverage$3,045100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,045 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$11,065
Medicare patients
92
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$26,617
TrulicityDulaglutide11$24,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$20,833
OzempicSemaglutide14$18,670
Spiriva RespimatTiotropium Bromide12$13,224
Emgality PenGalcanezumab-Gnlm15$9,964
SymbicortBudesonide/Formoterol Fumarate11$5,863
Albuterol Sulfate HfaAlbuterol Sulfate108$4,513
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,324
Ventolin HfaAlbuterol Sulfate19$1,787
Fluoxetine Hcl33$1,678
Levothyroxine Sodium74$1,248
Atorvastatin Calcium113$1,148
Omeprazole78$1,002
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$26,61723 claims
Lilly USA, LLCTrulicity$203$24,05311 claims
GSKTrelegy Ellipta$58$20,83320 claims
Novo NordiskOzempic$401$18,67014 claims
Boehringer IngelheimSpiriva Respimat$15$13,22412 claims
AstraZenecaSymbicort$282$5,86311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Holt

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →